Normal and Homozygous F508del mutation bronchial epithelial cell lines were treated with Everolimus (EVE) or Tacrolimus at different concentration. Biomolecular experiments demonstrated for the first time a dose-dependent EVE-induced EMT (Epithelial-Mesenchymal Transition) in airway cells. These results suggest that clinicians should employ, whether possible, low dosages of mTOR-Is. Further, genetic EMT profile in the future, whether validated in patients, could be useful for clinicians to personalize mTOR-I treatment in solid organ transplant recipients minimizing the lung toxicity.